178 related articles for article (PubMed ID: 17602578)
1. Antisense oligodeoxynucleotide-conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition.
Mok H; Park JW; Park TG
Bioconjug Chem; 2007; 18(5):1483-9. PubMed ID: 17602578
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate.
Kim SH; Mok H; Jeong JH; Kim SW; Park TG
Bioconjug Chem; 2006; 17(1):241-4. PubMed ID: 16417275
[TBL] [Abstract][Full Text] [Related]
3. Self-crosslinked and reducible fusogenic peptides for intracellular delivery of siRNA.
Mok H; Park TG
Biopolymers; 2008 Oct; 89(10):881-8. PubMed ID: 18521895
[TBL] [Abstract][Full Text] [Related]
4. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
[TBL] [Abstract][Full Text] [Related]
5. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate.
Park K; Lee MY; Kim KS; Hahn SK
Biomaterials; 2010 Jul; 31(19):5258-65. PubMed ID: 20378167
[TBL] [Abstract][Full Text] [Related]
6. Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine).
Hwa Kim S; Hoon Jeong J; Chul Cho K; Wan Kim S; Gwan Park T
J Control Release; 2005 May; 104(1):223-32. PubMed ID: 15866348
[TBL] [Abstract][Full Text] [Related]
7. Intracellular tracking of protamine/antisense oligonucleotide nanoparticles and their inhibitory effect on HIV-1 transactivation.
Dinauer N; Lochmann D; Demirhan I; Bouazzaoui A; Zimmer A; Chandra A; Kreuter J; von Briesen H
J Control Release; 2004 May; 96(3):497-507. PubMed ID: 15120905
[TBL] [Abstract][Full Text] [Related]
8. Reducible siRNA dimeric conjugates for efficient cellular uptake and gene silencing.
Chung HJ; Hong CA; Lee SH; Jo SD; Park TG
Bioconjug Chem; 2011 Feb; 22(2):299-306. PubMed ID: 21222435
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA.
Jiang G; Park K; Kim J; Kim KS; Oh EJ; Kang H; Han SE; Oh YK; Park TG; Kwang Hahn S
Biopolymers; 2008 Jul; 89(7):635-42. PubMed ID: 18322932
[TBL] [Abstract][Full Text] [Related]
10. Target-specific gene silencing of layer-by-layer assembled gold-cysteamine/siRNA/PEI/HA nanocomplex.
Lee MY; Park SJ; Park K; Kim KS; Lee H; Hahn SK
ACS Nano; 2011 Aug; 5(8):6138-47. PubMed ID: 21739990
[TBL] [Abstract][Full Text] [Related]
11. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery.
Gomes dos Santos AL; Bochot A; Doyle A; Tsapis N; Siepmann J; Siepmann F; Schmaler J; Besnard M; Behar-Cohen F; Fattal E
J Control Release; 2006 May; 112(3):369-81. PubMed ID: 16644054
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid complexed to biodegradable poly L-arginine for targeted delivery of siRNAs.
Kim EJ; Shim G; Kim K; Kwon IC; Oh YK; Shim CK
J Gene Med; 2009 Sep; 11(9):791-803. PubMed ID: 19569085
[TBL] [Abstract][Full Text] [Related]
13. Significant and prolonged antisense effect of a multifunctional envelope-type nano device encapsulating antisense oligodeoxynucleotide.
Nakamura Y; Kogure K; Yamada Y; Futaki S; Harashima H
J Pharm Pharmacol; 2006 Apr; 58(4):431-7. PubMed ID: 16597360
[TBL] [Abstract][Full Text] [Related]
14. Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides.
Han SE; Kang H; Shim GY; Kim SJ; Choi HG; Kim J; Hahn SK; Oh YK
J Drug Target; 2009 Feb; 17(2):123-32. PubMed ID: 19012052
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-siRNA conjugate/reducible polyethylenimine complexes for targeted siRNA delivery.
Jang YL; Ku SH; Jin S; Park JH; Kim WJ; Kwon IC; Kim SH; Jeong JH
J Nanosci Nanotechnol; 2014 Oct; 14(10):7388-94. PubMed ID: 25942799
[TBL] [Abstract][Full Text] [Related]
16. Target specific systemic delivery of TGF-β siRNA/(PEI-SS)-g-HA complex for the treatment of liver cirrhosis.
Park K; Hong SW; Hur W; Lee MY; Yang JA; Kim SW; Yoon SK; Hahn SK
Biomaterials; 2011 Jul; 32(21):4951-8. PubMed ID: 21481451
[TBL] [Abstract][Full Text] [Related]
17. Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis.
Jiang G; Park K; Kim J; Kim KS; Hahn SK
Mol Pharm; 2009; 6(3):727-37. PubMed ID: 19178144
[TBL] [Abstract][Full Text] [Related]
18. A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery.
Shen Y; Wang B; Lu Y; Ouahab A; Li Q; Tu J
Int J Pharm; 2011 Jul; 414(1-2):233-43. PubMed ID: 21545832
[TBL] [Abstract][Full Text] [Related]
19. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels.
Lee H; Mok H; Lee S; Oh YK; Park TG
J Control Release; 2007 Jun; 119(2):245-52. PubMed ID: 17408798
[TBL] [Abstract][Full Text] [Related]
20. Reducible hyaluronic acid-siRNA conjugate for target specific gene silencing.
Park K; Yang JA; Lee MY; Lee H; Hahn SK
Bioconjug Chem; 2013 Jul; 24(7):1201-9. PubMed ID: 23731084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
